These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 19719389)

  • 1. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies.
    Tammana S; Huang X; Wong M; Milone MC; Ma L; Levine BL; June CH; Wagner JE; Blazar BR; Zhou X
    Hum Gene Ther; 2010 Jan; 21(1):75-86. PubMed ID: 19719389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
    Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
    J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
    Pegram HJ; Purdon TJ; van Leeuwen DG; Curran KJ; Giralt SA; Barker JN; Brentjens RJ
    Leukemia; 2015 Feb; 29(2):415-22. PubMed ID: 25005243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
    Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
    Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
    Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
    Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
    Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR; Press OW; Till BG
    J Immunother; 2018 Jan; 41(1):19-31. PubMed ID: 29176334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
    Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
    Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
    Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
    Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
    Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
    Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
    Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
    Front Immunol; 2020; 11():539654. PubMed ID: 33281809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
    Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
    Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
    Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
    Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
    Hoyos V; Savoldo B; Quintarelli C; Mahendravada A; Zhang M; Vera J; Heslop HE; Rooney CM; Brenner MK; Dotti G
    Leukemia; 2010 Jun; 24(6):1160-70. PubMed ID: 20428207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
    Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
    JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.